FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval
Regeneron’s proposal to lengthen EYLEA HD dosing intervals to 24 weeks hits a CRL roadblock. The wait for extended treatment…
FDA Grants Priority Review to Eylea HD for Macular Edema Following RVO
QUASAR Phase III study data show higher-dose aflibercept could reduce injection frequency for retinal vein occlusion patients. Bayer (Leverkusen, Germany)…
popular posts
latest posts
